Consistent with preclinical results obtained on the role of IL‐1 in tumour progression, IL‐1 receptor antagonists and anti‐IL‐1 monoclonal antibodies can inhibit primary tumour growth and metastasis in animal studies.126. Here, IL1B is linked to neoplasm.